美国食品和药物管理局批准了第一个2型糖尿病的通用利拉格,旨在提高获取率和降低成本. FDA approves first generic liraglutide for Type 2 diabetes, aiming to boost access and cut costs.

FDA 已批准每日注射 GLP-1 药物利拉鲁肽的第一个仿制药，用于治疗 2 型糖尿病，类似于 Ozempic 中的活性成分。 The FDA has approved the first generic version of the daily injectable GLP-1 medicine, liraglutide, for Type 2 diabetes, similar to the active ingredient in Ozempic. 这项批准旨在解决药物短缺问题,并向有这一条件的3 800多万美国人提供更负担得起的选择方案。 This approval aims to address drug shortages and provide more affordable options for over 38 million Americans with the condition. 常见副作用包括恶心、腹泻和食欲下降。 Common side effects include nausea, diarrhea, and decreased appetite. 该药物携带了甲状腺C细胞肿瘤风险增加的警告。 The drug carries a warning about increased risk of thyroid C-cell tumors.